WEKO3
アイテム
{"_buckets": {"deposit": "6accf7d7-5a74-4c35-8d20-1f8a1f19d1f6"}, "_deposit": {"created_by": 1, "id": "44884", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "44884"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00044884", "sets": ["1"]}, "author_link": ["445808", "445804", "445807", "445803", "445805", "445806"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2005-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "120", "bibliographicPageStart": "116", "bibliographicVolumeNumber": "35", "bibliographic_titles": [{"bibliographic_title": "Japanese Journal of Clinical Oncology"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "OBJECTIVE: The purpose of this study is to clarify the efficacy and toxicity of hyperfractionated radiation therapy (RT) for patients with nasopharyngeal cancer (NPC). METHODS: Twenty-two patients with NPC treated at our hospital between April 1994 and December 2002 were the subjects of this study. They received hyperfractionated RT with a fraction size of 1.2 Gy, with a median tumor dose of 72 Gy (range 64.8-80.4). During this study period, our institutional strategy for locoregionally advanced NPC included neoadjuvant or concurrent chemotherapy combined with hyperfractionated RT, and 17 patients received some forms of cisplatin-containing chemotherapy. RESULTS: With a median follow-up of 59 months, the estimated 5-year disease-free survival rate and overall survival rate were 72.7 and 85.2%, respectively. Acute hematological toxicities were acceptable and manageable. However, \u003e50% of patients required nutritional support, and experienced severe pharyngitis, skin reaction and body weight loss. With regard to late sequelae, one patient developed grade 3 osteomyelitis, and one patient each developed grade 4 passage disturbance and laryngeal edema. No patients experienced any grades of optic nerve injury or temporal lobe necrosis. CONCLUSIONS: Hyperfractionated RT using 1.2 Gy per fraction, for a total dose of 72 Gy, produces a comparable treatment outcome. Although deleterious neurological sequelae were not observed in this study, caution should be exercised regarding other late sequelae, such as osteomyelitis and passage disturbance.", "subitem_description_type": "Abstract"}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0368-2811", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Uno, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "445803", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasuda, Shigeo"}], "nameIdentifiers": [{"nameIdentifier": "445804", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Hisao"}], "nameIdentifiers": [{"nameIdentifier": "445805", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "宇野 隆", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "445806", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "安田 茂雄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "445807", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "伊東 久夫", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "445808", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Hyperfractionated Radiation Therapy for Locoregionally Advanced Nasopharyngeal Cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Hyperfractionated Radiation Therapy for Locoregionally Advanced Nasopharyngeal Cancer"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/44884", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-06-18"}, "publish_date": "2007-06-18", "publish_status": "0", "recid": "44884", "relation": {}, "relation_version_is_last": true, "title": ["Hyperfractionated Radiation Therapy for Locoregionally Advanced Nasopharyngeal Cancer"], "weko_shared_id": -1}
Hyperfractionated Radiation Therapy for Locoregionally Advanced Nasopharyngeal Cancer
https://repo.qst.go.jp/records/44884
https://repo.qst.go.jp/records/44884ce16473f-56dd-44db-b829-613230fac09a
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-06-18 | |||||
タイトル | ||||||
タイトル | Hyperfractionated Radiation Therapy for Locoregionally Advanced Nasopharyngeal Cancer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Uno, Takashi
× Uno, Takashi× Yasuda, Shigeo× Ito, Hisao× 宇野 隆× 安田 茂雄× 伊東 久夫 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | OBJECTIVE: The purpose of this study is to clarify the efficacy and toxicity of hyperfractionated radiation therapy (RT) for patients with nasopharyngeal cancer (NPC). METHODS: Twenty-two patients with NPC treated at our hospital between April 1994 and December 2002 were the subjects of this study. They received hyperfractionated RT with a fraction size of 1.2 Gy, with a median tumor dose of 72 Gy (range 64.8-80.4). During this study period, our institutional strategy for locoregionally advanced NPC included neoadjuvant or concurrent chemotherapy combined with hyperfractionated RT, and 17 patients received some forms of cisplatin-containing chemotherapy. RESULTS: With a median follow-up of 59 months, the estimated 5-year disease-free survival rate and overall survival rate were 72.7 and 85.2%, respectively. Acute hematological toxicities were acceptable and manageable. However, >50% of patients required nutritional support, and experienced severe pharyngitis, skin reaction and body weight loss. With regard to late sequelae, one patient developed grade 3 osteomyelitis, and one patient each developed grade 4 passage disturbance and laryngeal edema. No patients experienced any grades of optic nerve injury or temporal lobe necrosis. CONCLUSIONS: Hyperfractionated RT using 1.2 Gy per fraction, for a total dose of 72 Gy, produces a comparable treatment outcome. Although deleterious neurological sequelae were not observed in this study, caution should be exercised regarding other late sequelae, such as osteomyelitis and passage disturbance. | |||||
書誌情報 |
Japanese Journal of Clinical Oncology 巻 35, 号 3, p. 116-120, 発行日 2005-03 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0368-2811 |